Moderna and Merck reported on August 19, 2026, that their individualized mRNA treatment intismeran autogene—also known as intismeran, V940, or mRNA-4157—met the recurrence-free-survival and distant-metastasis-free-survival endpoints in the Phase 3 INTerpath-001 trial. The study tested intismeran with KEYTRUDA after complete surgical removal of high-risk melanoma, compared with KEYTRUDA alone. The companies described the result as statistically significant and clinically meaningful, but did not disclose the numerical size of the benefit.
That distinction matters. This is an important reported clinical milestone, not evidence that melanoma has been cured, nor proof that the treatment is approved or publicly available.
What Moderna and Merck reported from INTerpath-001
INTerpath-001 was a randomized, double-blind, placebo- and active-comparator-controlled global Phase 3 trial involving 1,137 people with completely resected stage IIB, IIC, III, or IV cutaneous melanoma. At a prespecified interim analysis, the combination met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant-metastasis-free survival.
Recurrence-free survival measures how long patients remain free of a return of cancer or death. Distant-metastasis-free survival focuses specifically on whether melanoma spreads to organs or sites away from the original tumor, again counting death as an event in the trial analysis.
The announcement does not include hazard ratios, absolute recurrence rates, confidence intervals, subgroup analyses, quality-of-life findings, or mature overall-survival results. In other words, the headline tells us that the predefined statistical targets were met, but not yet how large or durable the difference was for different groups of patients.
What the trial actually compared
The trial assigned participants in a 2:1 ratio to receive either intismeran plus KEYTRUDA or KEYTRUDA alone. Both groups came from the same high-risk, completely resected melanoma population, making the comparator arm central to interpreting the reported result.
| Trial dimension | Intismeran plus KEYTRUDA | KEYTRUDA alone |
| Population | Completely resected stage IIB–IV cutaneous melanoma | Completely resected stage IIB–IV cutaneous melanoma |
| Treatment design | Patient-specific mRNA neoantigen therapy combined with KEYTRUDA | KEYTRUDA alone |
| Trial allocation | Part of the 2:1 assignment to the combination arm | Part of the 2:1 assignment to the comparator arm |
| Reported primary endpoint | Recurrence-free survival endpoint met at the prespecified interim analysis | Comparator arm used for the trial comparison |
| Reported key secondary endpoint | Distant-metastasis-free survival endpoint met at the prespecified interim analysis | Comparator arm used for the trial comparison |
KEYTRUDA is the brand name for pembrolizumab, an anti-PD-1 immunotherapy. The drug was used in both arms, so the Phase 3 question was not whether patients should receive immunotherapy at all. It was whether adding a patient-specific mRNA treatment improved the outcomes measured by the trial.
Why this is called a personalized mRNA treatment
The process starts with the patient’s tumor mutation profile. Intismeran is designed around selected mutations that can produce neoantigens—molecular markers that are not found in the same form on ordinary healthy cells. The treatment can encode up to 34 patient-specific neoantigens.
The synthetic mRNA acts like a temporary set of instructions. Cells use it to produce the selected targets, giving the immune system a clearer pattern to recognize. T cells can then identify cells displaying those targets. KEYTRUDA blocks the PD-1 pathway, a checkpoint that can restrain T-cell activity, helping support the antitumor immune response.
The useful mental model is not a universal vaccine poured into identical bottles. It is a treatment designed around the mutation profile of an individual tumor, paired with an existing immune-checkpoint drug. That is also why the word “personalized” carries more weight here than it does in ordinary marketing copy.
This is treatment after surgery, not prevention
Despite the familiar “vaccine” label, intismeran is not intended to prevent melanoma from developing in healthy people. It is an adjuvant treatment: a therapy given after the visible cancer has been surgically removed, with the goal of reducing the chance that the disease returns.
That timing also explains why recurrence-free survival is so important in this trial. The participants had undergone complete resection, but high-risk melanoma can return later. The treatment is designed to help the immune system find and attack residual cancer cells that may remain after surgery.
The result therefore does not establish a preventive cancer vaccine, a cure, or a treatment for every form of melanoma. It concerns a specific post-surgery setting and a defined combination of therapies.
The number readers are still waiting for
The Phase 3 announcement confirms that the two prespecified efficacy endpoints were met, but it does not provide the numerical effect sizes needed to judge the scale of the benefit. A statistically significant result can be clinically important, but readers still need the underlying numbers to understand how much the outcome changed in absolute terms and which patients benefited most.
The earlier evidence is promising but belongs to a different study. A five-year follow-up from an earlier Phase 2b trial reported a 49% lower risk of recurrence or death and a 59% lower risk of distant metastasis or death for intismeran plus KEYTRUDA compared with KEYTRUDA alone. Those figures are not results from INTerpath-001 and should not be used as a substitute for its undisclosed Phase 3 measurements.
Mature overall-survival findings also remain separate from recurrence endpoints. The trial is continuing, and longer follow-up is needed to determine whether the combination helps patients live longer—not merely remain free of recurrence or distant metastasis for a measured period.
Availability and the next clinical steps
The Phase 3 announcement did not announce regulatory approval, a commercial launch, or a price for intismeran.
Merck and Moderna plan to present more detailed data at an international medical meeting and discuss regulatory submissions. Related individualized neoantigen studies are also reported in non-small-cell lung cancer, bladder cancer, and renal cell carcinoma. Those studies do not establish that the melanoma result will translate to those diseases.
The bottom line is refreshingly precise: INTerpath-001 reported success on two important interim endpoints in high-risk melanoma, putting individualized mRNA therapy on much firmer clinical ground. The next decisive step is not another slogan about a breakthrough. It is the full dataset—the size and durability of the benefit, its effect across patient groups, its quality-of-life impact, and whether the survival advantage ultimately extends beyond recurrence measures.
